Advanced glycation end products and diabetic nephropathy

American Journal of Therapeutics

Volumn 12, Issue 6, 2005, Pages 562-572

  Thomas, Merlin C ^a   Forbes, Josephine M ^a   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Advanced glycation; Diabetes; Diabetic nephropathy

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXO THIAZOLIDIN 5 YLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALT 946; AMINOGUANIDINE; ANTIOXIDANT; BENFOTIAMINE; BROMINE DERIVATIVE; CARBOXYMETHYLLYSINE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; GROWTH FACTOR; LYSINE DERIVATIVE; LYSOZYME; N (2 ACETAMIDOETHYL)HYDROZINECARBOXIMIDAMIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PENTOSIDINE; PEPSIN A; PHENACYLTHIAZOLIUM BROMIDE; PLATELET DERIVED GROWTH FACTOR; PYRIDOXAMINE; PYRROLINE 5 CARBOXYLATE REDUCTASE; SOMATOMEDIN C; THIAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CELL ADHESION; CELL DAMAGE; CELL GROWTH; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEUROPATHY; EXTRACELLULAR MATRIX; FLUORESCENCE; GENE OVEREXPRESSION; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; MICROANGIOPATHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN HYDROLYSIS; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; SOLUBILITY; TISSUE INJURY;

ANIMALS; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; OXIDATIVE STRESS;

EID: 28044449557     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000178769.52610.69     Document Type: Conference Paper

References (94)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
2. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001;17:436-143.
3. Soulis-Liparota T, Cooper ME, Dunlop M, et al. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia. 1995;38:387-394.
4. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol. 2003;75:95-108.
5. Soulis T, Thallas V, Youssef S, et al. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia. 1997;40:619-628.
6. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40:1328-1334.
7. Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91:11704-11708.
8. Gerrard JA. New aspects of AGEing chemistry: recent developments concerning the Maillard reaction. Aust J Chem. 2002;55:299-310.
9. Szweda PA, Friguet B, Szweda LI. Proteolysis, free radicals, and aging. Free Radic Biol Med. 2002;33:29-36.
10. Fu MX, Wells-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676-683.
11. Thornalley PJ, Westwood M, Lo TW, et al. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol. 1995;112:24-31.
12. Januszewski AS, Alderson NL, Metz TO, et al. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans. 2003;31:1413-1416.
13. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis. 2000;35:365-380.
14. Bai P, Phua K, Hardt T, et al. Glycation alters collagen fibril organization. Connect Tissue Res. 1992;28:1-12.
15. Hadley JC, Meek KM, Malik NS. Glycation changes the charge distribution of type I collagen fibrils. Glycoconj J. 1998;15:835-840.
16. Silbiger S, Crowley S, Shan Z, et al. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 1993;43:853-864.
17. Raabe HM, Hopner JH, Notbohm H, et al. Biochemical and biophysical alterations of the 7S and NC1 domain of collagen IV from human diabetic kidneys. Diabetologia. 1998;41:1073-1079.
18. Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int. 1997;52:1302-1312.
19. Nyengaard JR, Chang K, Berhorst S, et al. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes. 1997;46:94-106.
20. Krishnamurti U, Rondeau E, Sraer JD, et al. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem. 1997;272:27966-27970.
21. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108:1853-1863.
22. Tarsio JF, Wigness B, Rhode TD, et al. Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes. 1985;34:477-484.
23. Cooper ME, Thallas V, Forbes J, et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia. 2000;43:660-664.
24. Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003;17:1762-1764.
25. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest. 1993;91:2463-2469.
26. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol. 2003;75:95-108.
27. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343:1519-1522.
28. Reddy S, Bichler J, Wells-Knecht KJ, et al. N epsilon-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995;34:10872-10878.
29. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836-842.
30. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol. 1999;10:822-832.
31. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications. 2003;17:16-21.
32. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes. 1995;44:824-829.
33. Valencia JV, Weldon SC, Quinn D, et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem. 2004;324:68-78.
34. Deuther-Conrad W, Franke S, Sommer M, et al. Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. Kidney Int Suppl. 2001;78:S63-S66.
35. Thomas MC, Tsalamandris C, MacIsaac R, et al. Low molecular weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. (in press).
36. Verbeke P, Perichon M, Borot-Laloi C, et al. Accumulation of advanced glycation endproducts in the rat nephron: link with circulating AGEs during aging. J Histochem Cytochem. 1997;45:1059-1068.
37. Twigg SM, Cao Z, Mclennan SV, et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology. 2002;143:4907-4915.
38. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123-1137.
39. Schmidt A, Vianna M, Gerlach M, et al. Isolation and characterisation of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-14997.
40. Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes. 2002;51:3532-3544.
41. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261-268.
42. Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes. 2002;51:3532-3544.
43. Pettersson-Fernholm K, Forsblom C, Hudson BI, et al. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes. 2003;52:891-894.
44. Schlueter C, Hauke S, Flohr AM, et al. Tissue-specific expression patterns of the RAGE receptor and its soluble forms - a result of regulated alternative splicing? Biochim Biophys Acta. 2003;1630:1-6.
45. Li Y, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and distribution of advanced glycation endproducts receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A. 1996;93:11047-11052.
46. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med. 1995;1:1057-1061.
47. Miyazaki A, Nakayama H, Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med. 2002;12:258-262.
48. Kuniyasu A, Ohgami N, Hayashi S, et al. CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes. FEBS Lett. 2003;537:85-90.
49. Saito A, Nagai R, Tanuma A, et al. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. J Am Soc Nephrol. 2003;14:1123-1131.
50. McRobert EA, Gallicchio M, Jerums G, et al. The aminoterminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. J Biol Chem. 2003;278:25783-25789.
51. Pugliese G, Pricci F, Iacobini C, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. 2001;15:2471-2479.
52. He CJ, Zheng F, Stitt A, et al. Differential expression of renal AGE-receptor genes in NOD mice: possible role in non obese diabetic renal disease. Kidney Int. 2000;58:1931-1940.
53. He CJ, Koschinsky T, Buenting C, et al. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med. 2001;7:159-168.
54. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870-880.
55. Asano M, Fujita Y, Ueda Y, et al. Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product. Nephron. 2002;91:688-694.
56. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of LMW-AGE peptides by renal proximal tubular cells. Diabetologia. 1996;39:149-160.
57. Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14(suppl 3):S254-S258.
58. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int. 2003;63:464-473.
59. Osicka TM, Yu Y, Panagiotopoulos S, et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes. 2000;49:87-93.
60. Lal MA, Brismar H, Eklof AC, et al. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int. 2002;61:2006-2014.
61. Sugimoto H, Shikata K, Wada J, et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia. 1999;42:878-886.
62. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol. 1999;10:822-832.
63. Odetti P, Traverso N, Cosso L, et al. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia. 1996;39:1440-1447.
64. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;11:17810-17814.
65. Thornalley PJ, Westwood M, Lo TW, et al. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol. 1995;112:24-31.
66. Yim MB, Yim HS, Lee C, et al. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci. 2001;928:48-53.
67. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA. 1994;91:7742-7746.
68. Rosca MG, Monnier VM, Szweda LI, et al. Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am J Physiol Renal Physiol. 2002;283:F52-F59.
69. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003;419:31-40.
70. Soulis T, Cooper ME, Vranes D, et al. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. 1996;50:627-634.
71. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001;44:108-114.
72. Wilkinson-Berka JL, Kelly DJ, Koerner SM, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes. 2002;51:3283-3289.
73. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002;61:939-950.
74. Metz TO, Alderson NL, Thorpe SR, et al. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys. 2003;419:41-49.
75. Chen AS, Taguchi T, Aoyama S, et al. Antioxidant activity of a Schiff base of pyridoxal and aminoguanidine. Free Radic Biol Med. 2003;35:1392-1403.
76. Miyata T, Ueda Y, Asahi K, et al. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol. 2000;11:1719-1725.
77. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 1999;42:579-588.
78. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294-299.
79. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 2003;52:2110-2120.
80. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89-96.
81. Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys. 2003;412:42-46.
82. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827-2835.
83. Zheng F, Cai W, Mitsuhashi T, et al. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy? Mol Med. 2001;7:737-747.
84. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;10:6474-6479.
85. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997;94:13915-13920.
86. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596-15601.
87. Nicholl ID, Stitt AW, Moore JE, et al. Increased levels of advanced glycation end products in the lenses and blood vessels of cigarette smokers. Mol Med. 1998;4:594-601.
88. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728-731.
89. Fonarow GC, Watson KE. Effective strategies for long-term statin use. Am J Cardiol. 2003;92:27i-34i.
90. Appel G, Bolton K, Freedman B, et al. Pimagedine lowers total urinary protein and slows progression of overt diabetic nephropathy in patients with type 1 diabetes mellitus. J Am Soc Nephrol. 1999;10:153A.
91. Brown CD, Zhao ZH, Thomas LL, et al. Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. Am J Kidney Dis. 2001;38:1414-1420.
92. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation endproduct cross-link breaker. Circulation. 2001;104:1464-1470.
93. Data Presented at Ninth Annual Scientific session of the Society of Geriatric Cardiology [http://www.pharmalive. com/news/show_article].
94. Davis BJ, Forbes JM, Thomas MC, et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia. 2004;47:89-97.